None.
| • | Chronic intravenous (IV) infusions delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of bloodstream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration. |
| • | Do not abruptly lower the dose or withdraw dosing. |
| • | Treprostinil injection may cause symptomatic hypotension. |
| • | Titrate slowly in patients with hepatic insufficiency because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function. |
| • | Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding. |
During clinical trials with SC infusion of treprostinil, infusion site pain and infusion site reaction (e.g., erythema, induration, or rash) were the most common adverse events and occurred in majority of those treated with treprostinil. Infusion site reactions were sometimes severe and led to discontinuation of treatment. Rash and hypotension (14% and 4%, respectively) were also commonly reported with SC infusion of treprostinil. Other common adverse events (≥3% more than placebo) included headache, diarrhea, jaw pain, edema, vasodilatation, and nausea, and these are generally considered to be related to the pharmacologic effects of treprostinil, whether administered subcutaneously or intravenously. The adverse reactions reported with treprostinil IV included bloodstream infections, arm swelling, paresthesia, hematoma, and pain.
Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
| • | Safety and effectiveness of Treprostinil injection in pediatric patients have not been established. |
| • | It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients. |
| • | There are no adequate and well-controlled studies with Treprostinil injection in pregnant women. |
| • | It is not known whether Treprostinil injection is excreted in human milk. |
Treprostinil injection is a prostacyclin mimetic indicated for
| • | Treatment of pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1 to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with New York Heart Association (NYHA) Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). |
| • | Patients who require transition from epoprostenol to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. |
None.
| • | Chronic intravenous (IV) infusions delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of bloodstream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration. |
| • | Do not abruptly lower the dose or withdraw dosing. |
| • | Treprostinil injection may cause symptomatic hypotension. |
| • | Titrate slowly in patients with hepatic insufficiency because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function. |
| • | Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding. |
During clinical trials with SC infusion of treprostinil, infusion site pain and infusion site reaction (e.g., erythema, induration, or rash) were the most common adverse events and occurred in majority of those treated with treprostinil. Infusion site reactions were sometimes severe and led to discontinuation of treatment. Rash and hypotension (14% and 4%, respectively) were also commonly reported with SC infusion of treprostinil. Other common adverse events (≥3% more than placebo) included headache, diarrhea, jaw pain, edema, vasodilatation, and nausea, and these are generally considered to be related to the pharmacologic effects of treprostinil, whether administered subcutaneously or intravenously. The adverse reactions reported with treprostinil IV included bloodstream infections, arm swelling, paresthesia, hematoma, and pain.
Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
| • | Safety and effectiveness of Treprostinil injection in pediatric patients have not been established. |
| • | It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients. |
| • | There are no adequate and well-controlled studies with Treprostinil injection in pregnant women. |
| • | It is not known whether Treprostinil injection is excreted in human milk. |
Treprostinil injection is a prostacyclin mimetic indicated for
| • | Treatment of pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1 to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with New York Heart Association (NYHA) Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). |
| • | Patients who require transition from epoprostenol to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. |
